The World Trade Organization, and the Present and Future of China’s Pharmaceutical Industry

Mei-ling Wang

Chapter 4 in WTO, Globalization and China’s Health Care System, 2007, pp 86-133 from Palgrave Macmillan

Abstract: Abstract China’s pharmaceutical industry is experiencing a period of high growth, in which global stakeholders have played an important role. The WTO framework has opened up new opportunities and challenges for the stakeholders in this sector. The purpose of this chapter is to examine the WTO and Trade Related Aspects of Intellectual Property Rights Agreement (TRIPS) rules related to the pharmaceutical industry as a whole; the WTO’s challenges to the regulatory and legal system in China, especially surrounding the patents issue, pharmaceutical quality control, price control, and the potential of Chinese herbal medicines; and the WTO’s overall impact on the development of indigenous pharmaceutical and biotech industries.

Keywords: Intellectual Property; Patent Application; Chinese Herbal Medicine; Patent Protection; Intellectual Property Right (search for similar items in EconPapers)
Date: 2007
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palchp:978-0-230-28696-2_4

Ordering information: This item can be ordered from
http://www.palgrave.com/9780230286962

DOI: 10.1057/9780230286962_4

Access Statistics for this chapter

More chapters in Palgrave Macmillan Books from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().